Sugi Predict

Sugi Predict / Targets / NR2C2

NR2C2

Nuclear receptor subfamily 2 group C member 2 · P49116 · NR2C2 on Sugi Atlas →

4,983 patent compounds predicted against NR2C2, 3,784 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3234828 SCHEMBL3234828 0.59 8/20
SCHEMBL3827617 SCHEMBL3827617 0.58 8/20
SCHEMBL5548581 SCHEMBL5548581 0.57 8/20
SCHEMBL3241401 SCHEMBL3241401 0.54 8/20
SCHEMBL1826484 SCHEMBL1826484 0.58 7/20
SCHEMBL3830805 SCHEMBL3830805 0.58 7/20
SCHEMBL3397844 SCHEMBL3397844 0.48 5/20
SCHEMBL2374752 SCHEMBL2374752 0.65 4/20
SCHEMBL1824771 SCHEMBL1824771 0.63 4/20
SCHEMBL2317748 SCHEMBL2317748 0.60 4/20
SCHEMBL1696223 SCHEMBL1696223 0.59 4/20
SCHEMBL2310430 SCHEMBL2310430 0.58 4/20
SCHEMBL3828768 SCHEMBL3828768 0.58 4/20
SCHEMBL2845348 SCHEMBL2845348 0.57 4/20
SCHEMBL1823606 SCHEMBL1823606 0.57 4/20
SCHEMBL5758924 SCHEMBL5758924 0.47 4/20
SCHEMBL2679815 SCHEMBL2679815 0.66 3/20
SCHEMBL3569663 SCHEMBL3569663 0.64 3/20
SCHEMBL2679102 SCHEMBL2679102 0.64 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL3566820) 0.64 3/20

Clinical trials — most relevant to NR2C2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation PHASE3COMPLETED
Effect of Metformin in Children With Type 1 Diabetes PHASE2/PHASE3COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women PHASE3COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease PHASE2COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease PHASE2COMPLETED
Phase II Study of Single Agent Lenvatinib PHASE2UNKNOWN
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Preoperative Bexarotene Treatment for Cushing's Disease PHASE1/PHASE2UNKNOWN
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer PHASE1/PHASE2RECRUITING
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer PHASE2UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Meclizine for Hepatocellular Carcinoma PHASE1COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Stress and Treatment Response in Puerto Rican Children With Asthma nanCOMPLETED
Expression of Steroid Receptors in Endometrium nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone nanCOMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? nanUNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NR2C2 binder may also engage these)

ProteinNameSimilarity
P49117 — 1.000 P49117 →
Q6GN21 — 1.000 Q6GN21 →
P55094 — 1.000 P55094 →
A0JNE3 — 1.000 A0JNE3 →
Q66J63 — 0.998 Q66J63 →
Q8VIJ4 — 0.996 Q8VIJ4 →
P28700 — 0.995 P28700 →
P06212 — 0.995 P06212 →
P06211 — 0.995 P06211 →
Q9TU15 — 0.994 Q9TU15 →
P13056 — 0.994 P13056 →
Q9XSB5 — 0.994 Q9XSB5 →
Q26622 — 0.994 Q26622 →
Q9YGL3 — 0.993 Q9YGL3 →
F1QLY4 — 0.993 F1QLY4 →
P51448 — 0.993 P51448 →
P51129 — 0.993 P51129 →
P49867 — 0.993 P49867 →
Q28CK1 — 0.993 Q28CK1 →
Q64249 — 0.992 Q64249 →
P19785 — 0.992 P19785 →
P81559 — 0.992 P81559 →
RXRA Retinoic acid receptor RXR-alpha 0.992 landscape →
Q9XSW2 — 0.992 Q9XSW2 →
Q95K90 — 0.992 Q95K90 →
Q06725 — 0.992 Q06725 →
Q9PU65 — 0.992 Q9PU65 →
Q5RCZ5 — 0.992 Q5RCZ5 →
NR2E1 Nuclear receptor subfamily 2 group E member 1 0.992 landscape →
Q0VC20 — 0.992 Q0VC20 →